Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
149.73
-2.35 (-1.55%)
At close: Apr 16, 2026, 4:00 PM EDT
149.73
0.00 (0.00%)
After-hours: Apr 16, 2026, 7:00 PM EDT
Revenue Breakdown
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 | Mar '20 Mar 31, 2020 |
|---|
Innovative Medicines Revenue | 13.34B | | | | | | | | | | | | | | | | | | | | | | | |
Innovative Medicines Revenue Growth | 1.39% | | | | | | | | | | | | | | | | | | | | | | | |
| 524.00M | | | | | | | | | | | | | | | | | | | | | | | |
| 13.86B | | | | | | | | | | | | | | | | | | | | | | | |
| 2.23% | | | | | | | | | | | | | | | | | | | | | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 | Mar '20 Mar 31, 2020 |
|---|
United States Revenue (Post-Q2 2023 Reporting) | 5.33B | | | | | | | | | | | | | | | | | | | | | | | |
United States Revenue (Post-Q2 2023 Reporting) Growth | -11.13% | | | | | | | | | | | | | | | | | | | | | | | |
Europe Revenue (Post-Q2 2023 Reporting) | 4.40B | | | | | | | | | | | | | | | | | | | | | | | |
Europe Revenue (Post-Q2 2023 Reporting) Growth | 11.13% | | | | | | | | | | | | | | | | | | | | | | | |
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) | 2.65B | | | | | | | | | | | | | | | | | | | | | | | |
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth | 14.40% | | | | | | | | | | | | | | | | | | | | | | | |
Canada and Latin America Revenue (Post-Q2 2023 Reporting) | 953.00M | | | | | | | | | | | | | | | | | | | | | | | |
Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth | 8.79% | | | | | | | | | | | | | | | | | | | | | | | |
| 524.00M | | | | | | | | | | | | | | | | | | | | | | | |
| 13.86B | | | | | | | | | | | | | | | | | | | | | | | |
| 2.23% | | | | | | | | | | | | | | | | | | | | | | | |
Revenue Breakdown 2
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 | Mar '20 Mar 31, 2020 |
|---|
Cardiovascular, Renal And Metabolic Revenue | 1.60B | | | | | | | | | | | | | | | | | | | | | | | |
Cardiovascular, Renal And Metabolic Revenue Growth | -33.38% | | | | | | | | | | | | | | | | | | | | | | | |
| 2.72B | | | | | | | | | | | | | | | | | | | | | | | |
Immunology Revenue Growth | 13.12% | | | | | | | | | | | | | | | | | | | | | | | |
| 1.63B | | | | | | | | | | | | | | | | | | | | | | | |
Neuroscience Revenue Growth | 25.77% | | | | | | | | | | | | | | | | | | | | | | | |
| 4.26B | | | | | | | | | | | | | | | | | | | | | | | |
| 11.30% | | | | | | | | | | | | | | | | | | | | | | | |
Established Brands Revenue | 3.13B | | | | | | | | | | | | | | | | | | | | | | | |
Established Brands Revenue Growth | -2.98% | | | | | | | | | | | | | | | | | | | | | | | |
| 13.86B | | | | | | | | | | | | | | | | | | | | | | | |
| 2.23% | | | | | | | | | | | | | | | | | | | | | | | |
Key Performance Indicators
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 | Mar '20 Mar 31, 2020 |
|---|
| 1.81B | | | | | | | | | | | | | | | | | | | | | | | |
| 13.22% | | | | | | | | | | | | | | | | | | | | | | | |
| 1.25B | | | | | | | | | | | | | | | | | | | | | | | |
| -42.52% | | | | | | | | | | | | | | | | | | | | | | | |
| 179.00M | | | | | | | | | | | | | | | | | | | | | | | |
| -56.45% | | | | | | | | | | | | | | | | | | | | | | | |
| 133.00M | | | | | | | | | | | | | | | | | | | | | | | |
| -36.67% | | | | | | | | | | | | | | | | | | | | | | | |
Updated Feb 4, 2026. Data Source:
Fiscal.ai.
